Tekmira Pharmaceuticals said this week that it has begun dosing patients in a phase I study of its siRNA-based cancer drug TKM-PLK1.

The agent targets polo-like kinase 1, a cell cycle protein involved in tumor cell proliferation, the company said.

"TKM-PLK1 has demonstrated anti-tumor efficacy in preclinical models of liver cancer, as well as tumors outside the liver, supporting our strong belief that PLK1 represents an excellent target for
RNAi," Tekmira President and CEO Mark Murray said in a statement.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PNAS this week: human cytomegalovirus diversity, patterns of homologous recombination in E. coli, and more.

US lawmakers are considering eliminating the medical devices tax that is part of the Affordable Care Act.

Two research teams in China home in on a gene that gives rice a long, slender shape.

Marcia McNutt, the editor-in-chief of Science, has been nominated to become president of the US National Academy of Sciences.